1Bengnér U,Johnell O,Redlund-Johnell I.Changes in incidence and prevalence of vertebral fractures during 30years[J].Calcif Tissue Int,1988,42(5):293-296.
2Kado DM,Browner WS,Palermo L,et al.Vertebral fractures and mortality in older women:aprospective study.Study of Osteoporotic Fractures Research Group[J].Arch Intern Med,1999,159(11):1215-1520.
1Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate[J]. Clin Ther, 2003, 25 (11): 2669-2708.
2Penning - van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy [J]. Osteoporos Int, 2008, 19 (4) : 511 -517.
3Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis [J]. Osteoporos Int, 2007, 18 (8):1023-1031.
4Black DM, Delmas PD, Eastell R, et al. Once - yearly zoledronic acid for treatment of postmenopausal osteoporosis [ J ]. N Engl J Med, 2007, 356 (18): 1809-1822.
5Lyles KW, Col6n - Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture[J]. N Engl J Med, 2007, 357 (18) : 1799 -1809.
6Lewiecki EM. Intravenous zoledronic acid tbr the treatment of osteoporosis[J]. Curr Osteoporos Rep, 2008, 6 (1): 17 -23.
7Reid IR, Miller P, Lyles K, et al. A single infusion of zoledronic acid improves remission rates in Paget's disease : a randomized controlled comparison with risedronate [J]. N Engl J Med, 2005, 353 (9) : 898 - 908.
10Reid IR,Brown JP,Burckhardt P,et al.Intravenous zoledronic acid in postmenopausal women with low bone mineral density[J].N Engl J Med,200,346(9):653-661.
